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Abstract: In this work, we present Thioflavin T fluorescence, transmission electron microscopy (TEM),
circular dichroism (CD), Fourier-transformed infrared (FT-IR), and oscillatory rheometry studies
applied to an antineoplastic drug, 5-fluorouracil (5-FU), embedded in a heterochiral tripeptide
hydrogel to obtain a drug delivery supramolecular system. The release of 5-fluorouracil was
monitored over time by reverse-phase high-performance liquid chromatography (HPLC) and its
interaction with the tripeptide assemblies was probed by all-atom molecular dynamics simulations.
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1. Introduction
Cancer is one of the most arduous ailments to treat that nowadays affects a large number of
people. Although progress has been made in leaps and bounds in research and oncology, the difficulty
of treatment persists to this day. The best treatment choice issue is directly correlated to the complexity
of the mechanisms involved in the transformation of healthy cells into cancerous ones and their
subsequent proliferation and spread to several sites in the body [1]. After a diagnosis of cancer,
the treatment of the patient consists of surgery (if applicable in the case of solid tumors) combined
with chemotherapeutic drugs and irradiation to reduce the number of malignant cells and tumor
reappearance [2,3]. Although skin cancer is not one of the most fatal tumors, it is known to be the most
widespread—every year in the United States, the number of patients diagnosed with skin cancer is
higher than the number of patients diagnosed with all the other cancers merged together [4].
Transdermal drug delivery systems (TDDS) of anticancer drugs are considered appropriate
vehicles to allow antineoplastic drugs to perform their action while also limiting common systemic
side effects (i.e., fatigue, infection, anemia, nausea and vomiting, diarrhea, etc.) [5]. Different
types of nanomaterials have been investigated as TDDS for skin cancer, such as liposomes [6]
and niosomes [7], solid lipid nanoparticles (SLNs) [8], polymeric micelles [9] and imprinted
nanospheres [10], dendrimers [11], nanotubes [12,13], magnetic nanoparticles [14], and hydrogels [15].
These systems permit the enhancement of the solubility of hydrophobic drugs so as to improve the
bioavailability and stability of the antineoplastic compounds and to extend their half-life. In the
last decades, the attention to hydrogels as drug delivery systems (DDS) has risen steadily due to
their ability to incorporate a high water content and the possibility of a “green” preparation, among
other reasons.
Supramolecular hydrogels based on short peptides have been studied as convenient vehicles
to deliver bioactive molecules and drugs [16] thanks to their facile preparation, low cost, and
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their biocompatibility and biodegradability, as required for bio-applications [17,18]. The formation
of a well-established three-dimensional (3D)-network through a self-assembly mechanism using
simple building blocks [19] has been largely exploited to load and release drugs [20]. In this
context, the use of a combination of D- and L-amino acids is a useful strategy to increase the
resistance against protease activity and to fine-tune self-assembly [21–23]. Previous examples of
low-molecular-weight gelators formed by heterochiral ultrashort peptides (consisting of just a few
amino acids) used as DDS were reported in the literature, including their non-covalent assembly with
non-steroidal anti-inflammatory drugs (NSAIDs) for prolonged delivery over time [24,25]. In particular,
D-Leu-Phe-Phe (Figure 1) is a well-established hydrogelator that was proven to assemble with the
hydrophobic drug ciprofloxacin [26], and, to a minor extent, NSAIDs [25]. The study of supramolecular
and biodegradable gel systems is a very important topic in drug delivery, to bring innovation and to
provide an alternative to polymers. In addition, despite the fact that various studies have been recently
reported in this area, at present there is still a very limited understanding of how such a system should
be designed so that a drug can participate in peptide assembly and fibril formation for prolonged
release. Isolated examples exist, but clear design rules that identify drug requirements for peptide
co-assembly have not yet emerged.
The aim of this work is to further explore the potential of D-Leu-Phe-Phe supramolecular gels
for drug delivery, by investigating for the first time its interaction with a hydrophilic drug of a
different therapeutic class, and thus with a different chemical structure relative to previous examples.
The long-term aim is to gather new insights for the identification of design rules for the co-assembly of
drugs and peptides into supramolecular hydrogels. We selected the antineoplastic drug 5-fluorouracil
(5-FU) (Figure 1) that acts as an antimetabolite and pyrimidine analog. 5-FU is the backbone of
chemotherapy regimens for the medical management of a wide variety of malignancies, including
solid tumors for which topical application is relevant. Moreover, the ability of 5-FU to antagonize
the immunosuppressive tumor microenvironment makes 5-FU attractive for an additional, positive
immunomodulatory effect for treatment consolidation [27]. However, 5-FU suffers from a short
biological half-life, and oral formulations have the key drawback of dosage variability, which is
particularly important given the low therapeutic index of 5-FU. For this reason, there is ample scope
for the development of innovative release formulations based on biodegradable vehicles, especially
where local delivery is appropriate [28]. In addition, nanostructured vehicles can have key advantages
as they allow the fine-tuning of the experimental partition coefficient of drugs, and they generally
display low diffusivity, which is desirable to maintain drugs in the target area when administered
locally [29].
5-FU is more hydrophilic than previous drugs tested for assembly with the D-Leu-Phe-Phe peptide
hydrogelator. However, aromaticity could be an important factor for enhancing drug interactions
with this peptide, and we reasoned that the ability to participate in hydrogen bonding may also favor
non-covalent interactions to establish a supramolecular hydrogel system. The fact that the peptide
self-assembly also occurs in the presence of large amounts of a hydrophilic component is not to
be taken for granted; in a previous study, even small amounts of a hydrophilic component with a
diameter of 1–2 nm hindered the assembly of D-Leu-Phe-Phe [30]. Different techniques were used to
study the hydrogel, including oscillatory rheology, FT-IR, TEM, and circular dichroism (CD). In this
study, we also derived the melting temperature (Tm) from the CD data to further quantify differences
in the gel structure with or without the addition of a drug. Moreover, the drug release process
was followed by HPLC and drug–peptide interactions were investigated by molecular dynamics
calculations. For the first time, we used in silico studies to visualize the interaction between drug
molecules and the surface of a peptide stack, both in parallel and antiparallel arrangements, and they
proved useful to confirm the nature, the distance, and the duration of drug–peptide interactions to
rationalize experimental observations.
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Figure 1. Chemical structures of D-Leu-Phe-Phe and 5-fluorouracil (5-FU). 
2. Results and Discussion 
The heterochiral tripeptide D-Leu-Phe-Phe was synthesized and characterized by NMR and LC-
MS (Figures S1–S5). It is a well-established gelator at neutral pH in phosphate buffer and has showed 
promising biocompatibility in vitro [26]. Firstly, the peptide was dissolved at alkaline pH (with or 
without the drug), thanks to the repulsion between the negative charges in its anionic state. 5-FU 
stability under the alkaline conditions required for hydrogel preparation was confirmed by NMR 
analysis (Figures S6–S8). Self-assembly occurred upon the addition of a mildly acidic buffer solution 
to lower the pH to neutral, the condition at which the peptide is a zwitterion. The final concentration 
of 5-FU loaded on the peptide-based hydrogel was chosen within the range of topic preparation 
concentrations already available on the market (0.5% Carac®, 1% Fluoroplex®, 4% Tolak®, 5% 
Efudex®).  
2.1. Hydrogel Characterization 
The hydrogel obtained from the tripeptide in combination with 5-FU was stable and self-
supported (Figure 2) and its viscoelastic nature was assessed by oscillatory rheometry studies (Figure 
3). The presence of 5-FU did not give rise to any significant difference in terms of the kinetics of 
hydrogel formation, which was very rapid in both cases and reached a plateau within approximately 
10 minutes. The storage modulus G’ for the peptide hydrogel was slightly increased in the presence 
of 5-FU (see Figure S9). The stress sweep analysis confirmed a slightly lower resistance for the peptide 
hydrogel upon drug inclusion, i.e., the crossover that indicates gel-to-sol transition occurs at 55 Pa 
with the drug and at 80 Pa for the vehicle alone, suggesting a lower level of cross-linking within the 
gel matrix in the former case (Figure 3, bottom) [31].   
 
Figure 2. Self-supporting hydrogels obtained: D-Leu-Phe-Phe alone (left) and with 5-FU (right). 
Figure 1. Chemical structures of D-Leu-Phe-Phe and 5-fluorouracil (5-FU).
2. Results and Discussion
The heterochiral tripeptide D-Leu-Phe-Phe was synthesized and characterized by NMR and
LC-MS (Figu es S1–S5). It is a well-established gelator at neutr l pH in phosphate buffer has
showed promising biocompatibility in vitro [26]. Firstly, the peptide was dissolved at alkaline pH
(with or with ut the drug), thanks to the repu sion between the negative charges in its anionic state.
5-FU stability nder the alkaline conditions required for hydrogel p eparation was confirmed by
NMR analysis (Figures S6–S8). Self-a sembly occurred upon the additi of a mildly acidic buffer
solution to lower the pH to neutral, the ondition at which the peptide is a zwitterion. The final
c ncentration of 5-FU loaded on the peptide-based hydrog l was chosen wit in the rang of topic
preparati n conce trations already available n the market (0.5% Carac®, 1% Flu roplex®, 4% Tolak®,
5% Efudex®).
2.1. Hydrogel Characterization
The hydrogel obtained from the tripeptide in combination with 5-FU was stable and self-supported
(Figure 2) and its viscoelastic nature was assessed by oscillatory rheometry studies (Figure 3).
The presence of 5-FU did not give rise to any significant difference in terms of the kinetics of hydrogel
formation, which was very rapid in both cases and reached a plateau within approximately 10 minutes.
The storage odulus G’ for the peptide hydrogel was slightly increased in the presence of 5-FU (see
Figure S9). The stress sweep analysis confirmed a slightly lower resistance for the peptide hydrogel
upon drug inclusion, i.e., the crossover that indicates gel-to-sol transition occurs at 55 Pa with the drug
and at 80 Pa for the vehicle alone, suggesting a lower level of cross-linking within the gel matrix in the
former case (Figure 3, bottom) [31].
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2.2. Nanostructure Morphology 
TEM was used to study the nanomorphology of each system (i.e., the hydrogel without or with 
5-FU) (Figure 4). The overall morphologies of the two materials appeared to be very similar 
regardless of the presence of 5-FU. Individual fibrils formed by the peptide were 10.3 ± 1.7 nm wide; 
the inclusion of 5-FU resulted in a very minor but statistically significant (p < 0.001) difference in 
diameter, which was reduced to 9.1 ± 2.1 nm (n = 100). In both cases, the hierarchical assembly of 
fibrils into fibers, either straight or with irregular twists, was evident, as well as their further 
association into bundles. The median diameter was approximately 50 nm, but samples with 5-FU 
were more heterogeneous with a wider distribution (Figure 4). Overall, TEM micrographs were 
comparable to those reported in previous studies for a similar system, whereby the inclusion of 
NSAIDs resulted in slightly thinner fibrils [25].  
A convenient method to estimate conformational modifications in a β-rich structure, such as 
amyloid structures, is the Thioflavin T fluorescence assay (see Figure S10) [32]. The principle behind 
the test concerns the use of a benzothiazole dye able to bind to the surface of amyloid fibrils, with 
consequent fluorescence [33]. This phenomenon is due to the limited rotation of the single bond 
between two aromatic portions of the dye (i.e., the benzothiazole and a substituted benzene) upon 
non-covalent binding to an amyloid surface [34]. Thioflavin T was able to bind onto the fibers’ surface 
to yield a noteworthy fluorescence emission, with no significant difference upon the inclusion of the 
drug (Figure S10). This result indicated that an analogous amyloid surface area was present with or 
without the drug, consistent with the TEM images that revealed an overall analogous median 
diameter of the fibers. 
Figure 3. Oscillatory rheometry analysis of hydrogels with the peptide alone (left) or with 5-FU (right).
2.2. Nanostructure Morphology
TEM was used to study the nanomorphology of each system (i.e., the hydrogel without or
with 5-FU) (Figure 4). The overall morphologies of the two materials appeared to be very similar
regardless of the presence of 5-FU. Individual fibrils formed by the peptide were 10.3 ± 1.7 nm wide;
the inclusion of 5-FU resulted in a very minor but statistically significant (p < 0.001) difference in
diameter, which was reduced to 9.1± 2.1 nm (n = 100). In both cases, the hierarchical assembly of fibrils
into fibers, either straight or with irregular twists, was evident, as well as their further association
into bundles. The median diameter was approximately 50 nm, but samples with 5-FU were more
heterogeneous with a wider distribution (Figure 4). Overall, TEM micrographs were comparable to
those reported in previous studies for a similar system, whereby the inclusion of NSAIDs resulted in
slightly thinner fibrils [25].
convenient method to estimate conformational modifications in a β-rich structure, such as
amyloid structures, is the Thi flavin T flu rescence assay (see Figure S10) [32]. The principle behind
the test concerns the us of a benzothiazole dy able to bind to the surface of amyloid fibrils,
with consequ nt fluore cence [33]. This phenomenon is due to the limited rotation of the single
bond between two aromatic portions of the dye ( .e., the benzothiazole and a substituted benzene)
upon no -covalent binding t an amyloid surface [34]. Thioflavin T w s a le o bind onto the fibers’
surface to yield a notew rthy fluorescence mission, with o significant differe ce upon the inclusion
of the drug (Figure S10). This result indicated that an a alogous amyloid surfac area was pres nt
with or without the drug, consistent with the TEM images that revealed an overall analogous median
diameter of the fibers.
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shifts and only a minor reduction of intensity of the minima at 204 and 215 nm in the presence of 5-
FU. CD studies over the first hour of assembly confirmed a very minor effect played by 5-FU, which 
overall led to a slight decrease in self-assembly kinetics (Figure S11). This is consistent with the 
rheological and TEM data discussed above, which showed only very minor changes in self-assembly 
upon drug inclusion. 
A heating ramp from 25 to 85 °C was then applied to both systems to reveal the high thermo-
resistance of these materials (Figure S12). Surprisingly, the melting temperature (Tm) was slightly 
increased from 58 to 63 °C upon the inclusion of 5-FU in the system, and overall disassembly occurred 
over a wider range of temperatures (Figure 5), suggesting a more heterogeneous supramolecular 
system in the presence of the drug. This finding was in agreement with the TEM observations that 
revealed a wider distribution of fiber diameters for the drug-loaded hydrogel.  
Figure 4. TEM micrographs of ti drogel without (left) or with 5-FU (right). Median fiber
diameters wer 49 ± 14 n 27 nm, respectively (n = 100, p = 0.02).
2.3. Spectroscopic Study of Peptide Confor ation
To investigate changes in pepti ation after the loading of this anti ancer drug, ci cular
dichroism (CD) analysi was performed ( i 5 an Figure S11). Th p ptide negative signals in the
200– 20 nm region due to the amide bond were present with and without the drug, with no significant
shifts and only a minor reduction of intensity of the minima at 204 and 215 nm in the presence of
5-FU. CD studies over the first hour of assembly confirmed a very minor effect played by 5-FU,
which overall led to a slight decrease in self-assembly kinetics (Figure S11). This is consistent with the
rheological and TEM data discussed above, which showed only very minor changes in self-assembly
upon drug inclusion.
A heating ramp from 25 to 85 ◦C was then applied to both systems to reveal the high
thermo-resistance of these materials (Figure S12). Surprisingly, the melting temperature (Tm)
was slightly increased fro 58 to 63 ◦C upon the inclusion of 5-FU in the system, and overall
disas embly occurred over a wi er range of temper tures (Figure 5), sugg sting a mo e heterogeneous
supramolecular system in the pres nce of he drug. This fin ing was in agreement with the TEM
observations that revealed a wider distribution of fiber diameters for the drug-loaded hydrogel.
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particular, approximately half of the drug loading was released within the first half-hour, and the 
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the initial 60% of cumulative drug release (Figure 6, right). Therefore, the drug was released notably 
faster relative to other drugs tested previously [25,26], although it should be noted that previous 
examples concerned drugs with a notably different chemical structure. Nevertheless, drug release for 
5-FU followed a kinetics model analogous to that of the naproxen-loaded peptide hydrogel, for which 
experimental data suggested drug–peptide interactions, although to only a small extent [25]. It would 
be tempting to simply attribute the limited drug–peptide interaction to drug hydrophilicity, which 
would prefer to interact with the buffer aqueous solution rather than with the hydrophobic 
tripeptide. Indeed, 5-FU is notably more hydrophilic (logP −0.89) [36] than ketoprofen (logP 3.12) [37], 
and naproxen (logP 3.18), which were previously tested for assembly with this peptide into a 
supramolecular hydrogel for drug delivery [26]. However, ciprofloxacin, which was shown to play a 
more active role in the assembly of the tripeptide relative to any of the other drugs mentioned above 
[27], displayed a significantly lower hydrophilicity (logP 0.28) [38]. Therefore, we did not observe 
any obvious trend between the drug release rate and drug hydrophobicity, suggesting that other 
factors likely play a role in the drug-peptide interactions. These may include the ability of drugs to 
engage in specific non-covalent interactions with the peptide. This aspect was thus investigated by 
means of all-atom molecular dynamics (AA-MD) simulations carried out in explicit water.  
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Fourier-transformed infrared (FT-IR) spectroscopy was also employed to assess peptide
conformation (Figure S13). The amide I region did not show significant shifts upon the inclusion of
5-FU in the system, in agreement with the CD and Thioflavin T fluorescence data. We can conclude that
peptide conformation was not affected by the presence of 5-FU, although the drug appeared to slightly
affect the distribution of fiber diameters, and thus the viscoelastic and thermo-resistance properties.
2.4. Drug Release Studies
Drug release into phosphate-buffered saline solution at 37 ◦C was monitored over time, and
analyzed by means of high-performance liquid chromatography (HPLC, Figure 6 and Figure S14).
5-FU solubility in water corresponds to 11.1 mg/mL [35], thus the drug was below its solubility limit
to maintain sink conditions. The hydrogels were prepared to adhere to the bottom of glass tubes,
so that the drug was released along the vertical direction through the surface of the hydrogels into the
overlying medium (Figure 6, left). Overall, hydrogel integrity was preserved during the experiment,
with no visible swelling. The very fast kinetics of drug release reached a plateau within 8 h, suggesting
a limited interaction between the h drogel matrix an the drug (Figure 6, center). In particular,
approximately half of the drug l ading was rel ase within the first half-hour, and the majority of the
drug was released during the first hour. During this time, th cumulative % drug release followed a
line r t end with the square oot of time. This r lea e profile was described by the empirical equation
of Ritger–Peppas, which can be applied to Fickian one-dimensional diffusion for the initial 60% of
cumulative dr g release (Figure 6, right). T erefor , the drug was released notably faster relative to
other drugs tested previously [25,26], although it should be not d that pr vio s examples concerned
drugs with a no ably diffe ent chemical structure. Nevertheless, drug re eas for 5-FU followed a
kinetics model analogous to that of the naproxen-load d peptide hydrogel, for which experimental
data suggested drug–peptide interactions, although o o ly a small ext nt [25]. It would be tempting
to simply attribute the limited rug–pe tide i t r ti to drug hydrophilicity, which would prefer to
interact with the buffer aqueous solution rather than with the hydrophobic tripepti e. Indeed, 5-FU is
notably more hydrophilic (logP −0.89) [36] than ket profen (l gP 3.12) [37], and naproxen (logP 3.18),
which were previously tested for assembly with this peptide into a supramolecular hydrogel for drug
delivery [26]. However, ciprofloxacin, which was shown to play a more active role in the assembly
of the tripeptide relative to any of the other drugs mentioned above [27], displayed a significantly
lower hydrophilicity (logP 0.28) [38]. Therefore, we did not observe any obvious trend between the
drug release rate and drug hydrophobicity, suggesting that other factors likely play a role in the
drug-peptide interactions. These may include the ability of drugs to engage in specific non-covalent
interactions with the peptide. This aspect was thus investigated by means of all-atom molecular
dynamics (AA-MD) simulations carried out in explicit water.
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Two stacks of six peptides, each in -sheet organization and arranged side by side, were selected 
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Simulations (1 µs long) showed a highly dynamic interaction between the drug and the peptides. 
Upon inspecting the trajectories, it appeared that the recognition was mainly driven by a π-π stacking 
between the phenylalanine and 5-FU rings (Figure 7). Transient hydrogen bonds, typically involving 
the carboxylic acid group and N1-H group of the 5-FU, were also detected for each time frame. The 
weak nature of the π-π stacking and the limited average number of temporary hydrogen bonds can 
explain the extremely transient interaction and the quick release of the drug from the hydrogel. To 
gain more insight into this dynamic behavior, we tracked the minimum distance between the heavy 
atoms (i.e., all not hydrogen atoms) of each 5-FU and D-Leu-Phe-Phe molecule over time (Figure S15). 
A cut-off range of 5 Å was assigned to define a 5-FU molecule bound to a stack and to count the 
number of drugs bonded at each time frame (Figure S16). It emerged clearly that 5-FU was able to 
interact, although weakly, with the peptides either in parallel or antiparallel arrangements. In fact, 
for most of the 5-FU molecules, the time evolution of the minimum distance fell below the contacting 
limit of 5 Å but with a highly oscillatory behavior, suggesting a transient and limited affinity of 5-FU 
toward D-Leu-Phe-Phe. Only for a few 5-FU molecules (as for instance those sampled in Figure S16) 
the binding event lasted more than 100 ns. On average, six (out of 16) 5-FU molecules stayed in 
contact with the hydrogel, regardless of its organization, again supporting the weak nature of the 
interaction forces involved. 
Figure 6. Drug release study for 5-FU monitored by reverse-phase HPLC.
2.5. Molecular Modeling of D-Leu-Phe-Phe/5-FU Interaction
Two stacks of six peptides, each in β-sheet organization and arranged side by side, were selected
as a minimum representative system for the local D-Leu-Phe-Phe fiber structure [39,40]. Either parallel
or antiparallel configurations were considered for the hydrogel arrangement. The ratio between
D-Leu-Phe-Phe and 5-FU was chosen to mimic the experimental concentrations, meaning that 16 5-FU
molecules were positioned initially close to each D-Leu-Phe-Phe stack.
Simulations (1 µs long) showed a highly dynamic interaction between the drug and the peptides.
Upon inspecting the trajectories, it appeared that the recognition was mainly driven by a pi-pi stacking
between the phenylalanine and 5-FU rings (Figure 7). Transient hydrogen bonds, typically involving
the carboxylic acid group and N1-H group of the 5-FU, were also detected for each time frame.
The weak nature of the pi-pi stacking and the limited average number of temporary hydrogen bonds
can explain the extremely transient interaction and the quick release of the drug from the hydrogel.
To gain more insight into this dynamic behavior, we tracked the minimum distance between the heavy
atoms (i.e., all not hydrogen atoms) of each 5-FU and D-Leu-Phe-Phe molecule over time (Figure S15).
A cut-off range of 5 Å was assigned to define a 5-FU molecule bound to a stack and to count the
number of drugs bonded at each time frame (Figure S16). It emerged clearly that 5-FU was able to
interact, although weakly, with the peptides either in parallel or antiparallel arrangements. In fact,
for most of the 5-FU molecules, the time evolution of the minimum distance fell below the contacting
limit of 5 Å but with a highly oscillatory behavior, suggesting a transient and limited affinity of 5-FU
toward D-Leu-Phe-Phe. Only for a few 5-FU molecules (as for instance those sampled in Figure S16)
the binding event lasted more than 100 ns. On average, six (out of 16) 5-FU molecules stayed in contact
with the hydrogel, regardless of its organization, again supporting the weak nature of the interaction
forces involved.
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Figure 7. All-atom molecular dynamics (AA-MD) snapshots (left) and corresponding molecular 
surface (right) of D-Leu-Phe-Phe stacks in presence of 5-FU. (a–b) and (c–d) images refer to 
antiparallel and parallel β-sheet conformations, respectively. The peptide backbone is depicted in 
grey and the L/F-side chains are depicted in light and dark green, respectively. 5-FU molecules are 
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Figure 7. All-atom molecular dynamics (AA-MD) snapshots (left) and corresponding molecular surface
(right) of D-Leu-Phe-Phe stacks in presence of 5-FU. (a–b) and (c–d) images refer to antiparallel and
parallel β-sheet conformations, respectively. The peptide backbone is depicted in grey and the L/F-side
chains are depicted in light and dark green, respectively. 5-FU molecules are represented as orange
sticks. Water and ions are not shown for clarity.
3. Conclusions
Drug delivery and sustained release over time present several challenges to overcome. This work
explored 5-FU, the first example of a hydrophilic drug of very different chemical structure relative to
previous cases, as a drug potentially able to interact non-covalently with a self-assembling tripeptide
by means of aromatic interactions and hydrogen bonding. These transient interactions were confirmed
by in silico studies on peptide stacks, both in parallel and antiparallel arrangements. The overall aim
was to assess whether the tripeptide was able to gel in the presence of the drug at levels relevant
to those used for therapy, and whether the drug played an active role in assembly for its prolonged
release over time.
Drug-loaded hydrogels were obtained successfully at physiological conditions, with only minor
effects on the viscoelastic properties of the final soft materials. TEM micrographs revealed that the
overall morphology of peptide assemblies was not altered by the presence of 5-FU, although some
minor differences in terms of fibril and fiber size were noted. Circular dichroism, FT-IR, and Thioflavin
T fluorescence analyses suggested that peptide conformation was not altered by 5-FU, nor was the
resulting amyloid surface. CD supported the rheology and TEM data, as it revealed a minor effect
played by the drug on the assembly size distribution, and thus on the hydrogel thermo-resistance.
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5-FU release proceeded faster than any other drug tested before with this system [25,26], although
no obvious trend between drug release rate and drug hydrophobicity was noted. This observation
suggested that other factors come into play. Molecular simulations indeed revealed transient hydrogen
bonding as well as pi-pi interactions, as previously hypothesized for naproxen, which unexpectedly
was released following the same kinetic model as 5-FU, although at a slower rate [25].
In conclusion, this work showed that antitumoral drugs can also be embedded into a
supramolecular hydrogel otherwise composed solely of a tripeptide, and at concentrations that are
relevant to those used in the clinic. Despite its hydrophilicity, the aromatic nature of 5-FU as well as
its ability to engage in hydrogen bonding led us to believe it may be retained to some extent by the
hydrogel matrix. Drug release experiments actually showed that 5-FU was released completely within
the first few hours, suggesting the absence of a strong interaction with the peptide assemblies. In silico
investigation assisted us in the understanding and quantification of the interactions between drug and
peptide molecules that determine the resulting structure, and hence the material behavior. Overall,
experimental and theoretical data suggested that pi-pi interaction and hydrogen bonding were present,
although transiently. Future studies will explore other structural features of drug molecules in the
quest to identify rules for drug–peptide co-assembly into a supramolecular hydrogel capable of a slow
drug release over a number of days.
4. Materials and Methods
4.1. Materials
The 2-chlorotrytil resin O-benzotriazole-N,N,N,N-tetramethyl-uronium-hexafluoro-phosphate
(HBTU) and Fmoc-protected D-leucine were bought from GL Biochem (Shanghai) Ltd. (Shanghai,
China), while Fmoc-protected phenylalanine was bought from Iris Biotech GmbH (Marktredwitz,
Germany). All solvents were bought from Merck (Milan, Italy) and were of HPLC grade. Chemical
reagents were provided by Sigma (Milan, Italy). Milli-Q-water (MQ water) of high purity and with a
resistivity higher than 18 MΩ cm was dispensed by an in-line Millipore RiOs/Origin apparatus (Merck,
Milan, Italy). The NMR spectra were recorded on a Varian Innova Instrument (Agilent Technologies,
Milan, Italy) at 400 MHz for 1H, and at 100 MHz for 13C. Tetramethylsilane was used as an internal
standard and chemical shifts were reported as ppm. Electrospray MS spectra were obtained with an
Infinity 6120 single quadrupole LC-MS system (Agilent Technologies, Milan, Italy).
4.2. Peptide Synthesis and Purification
Peptide synthesis was performed according to standard Fmoc solid phase peptide synthesis
(SPPS) with HBTU activation procedures. In short, SPPS was performed in a glass reactor with
a sintered glass filter, and Fmoc-amino acid deprotection was achieved with 20% piperidine in
N,N-dimethylformamide (DMF) for 20 min (2 × 10 min) with continuous stirring, until both
bromophenol blue and acetaldehyde/chloranil tests turned positive after extensive washings with
DMF/DCM. Then, 2.0 equiv. of Fmoc-amino acid was activated in DMF with 1.5 equiv. of HBTU and
1.5 equiv. of HOAt in DMF (4 mL for every equiv. of resin), with the addition of N,N-diisopropyl ethyl
amine (DIPEA) in which 2 mL of a 1 M solution in DMF was added for each equiv. of resin. In the
same glass reactor, peptide coupling was attained for 1.5 h at room temperature, and completeness was
monitored by colorimetric tests as noted above. The peptide was cleaved from the resin with a mixture
of TFA/DCM/TIPS/water (47.5:47.5:2.5:2.5) (TFA: trifluoroacetic acid; TIPS: triisopropyl silane).
The resulting solution was concentrated to an oil under air flow, and purification was performed by
reverse-phase HPLC (Agilent Technologies, Santa Clara, CA, USA) by dissolving the oil in a mixture of
acetonitrile/water. The HPLC Agilent 1260 Infinity apparatus was composed of a preparative gradient
pump (1311B), an autosampler (G1329B), a C-18 column (Kinetex, 5 microns, 100 Å, 250 mm × 10 mm,
Phenomenex, Torrance, CA, USA), and a Photodiode Array detector (G1315C). The mobile phase was
composed of acetonitrile (MeCN) and water with 0.05% TFA with the program as follows: 30% MeCN
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for the first 2 min; 65% MeCN at t = 9 min; 95% MeCN at t = 11 min; and finally 95% MeCN was
maintained until 14 min (retention time tR = 8.5 min). The pure peptide was then lyophilized to a
white fluffy powder, and it was identified by 1H-NMR, 13C-NMR, and ESI-MS.
4.3. Hydrogel Preparation
The peptide was dissolved in sodium phosphate buffer (0.1 M pH 12.0), and then the same volume
of sodium phosphate at an acidic pH (0.1 M pH 5.8) was added to reach a final peptide concentration
of 10 mM (final pH of 7.2 ± 0.1). All buffer solutions were filtered (0.2 µm) prior to use. In the case of
the hydrogels containing 5-FU, the peptide was dissolved in sodium phosphate buffer (0.1 M pH 11.8),
in which a specific amount (5% of the final volume of the hydrogel) of 5-fluorouracil in 1 M NaOH
(from a stock freshly prepared) was added. As last step, half of the final volume of the hydrogel of
sodium phosphate monobasic dihydrate (0.1 M pH 4.5) was added to obtain a final pH of 7.3 ± 0.1.
The final concentrations of the peptide D-Leu-Phe-Phe and of 5-FU were respectively 10 mM and
13 mM. All buffer solutions were filtered (0.2 µm) prior to use.
4.4. Oscillatory Rheometry
A Malvern Kinexus Ultra Plus Rheometer (Alfatest, Milan, Italy) equipped with a 20-mm stainless
steel parallel plate geometry was used at the temperature of 25 ◦C in a Peltier system (Alfatest, Milan,
Italy). Hydrogels were assembled in situ and measurements were taken immediately with a gap set
to 1.00 mm. Kinetics were studied over 30 minutes at a set frequency of 1.00 Hz and a set stress of
2 Pa. Next, frequency sweeps were obtained with a set stress of 2 Pa, and finally stress sweeps were
measured with a controlled frequency of 1 Hz.
4.5. Transmission Electron Microscopy
TEM images were acquired on a Talos F200X, FEI, operating at 80 kV (Thermo Fisher Scientific,
Waltham, MA, USA) using TEM grids (copper-grid-supported carbon film). Gels prepared 24 h before
were carefully deposited on the grid for TEM analysis. They were then dried at room temperature for
15 min and aqueous tungsten phosphate solution (pH 7.4) was used as a contrast agent. The dimensions
of the nanostructures were determined by considering 100 measurements.
4.6. Circular Dichroism
A Jasco J-815 Spectropolarimeter (Jasco Europe, Cremella, Italy) was used with one accumulation,
1-s integrations, a bandwidth of 1 nm, and a step size of 1 nm, over a range of wavelengths from 190 to
280 nm at 25 ◦C. Hydrogel samples were prepared directly in a 0.1-mm quartz cell.
4.7. Fourier-Transformed Infrared Spectroscopy
FT-IR spectra were acquired at 1 cm−1 resolution and 128 accumulations in a Perkin Elmer System
2000 (Perkin Elmer, Milan, Italy) with the KBr-pellet method. After 24 h of assembly, hydrogel samples
were dried in vacuo. The resulting powder was mixed with KBr to obtain a pellet.
4.8. Thioflavin T Fluorescence Assay
The assay was performed in an Infinite M1000 pro (Tecan, Milan, Italy) system using Greiner 96 U
Bottom Black Polystyrene plates (VWR, Milan, Italy), into which 150 µL of hydrogels were prepared
directly inside the wells. After 1 h of assembly, 30 µL of a solution of Thioflavin T (29.1 µM in 20 mM
glycine-NaOH pH 7.5, which was previously filtered with a 0.2-µm filter) was dispensed into the
wells. Fluorescence emission was analyzed after 15 min using 446 nm as the excitation wavelength and
490 nm as the emission wavelength (with a 20 nm bandwidth). Each analysis was done in triplicate
and the experiment was performed twice (n = 6). Microsoft Excel software was used to calculate the
average and standard deviations.
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4.9. Drug Release Assay
For each drug-containing hydrogel, six different samples were prepared as described above
(0.250 mL total volume) in a glass tube and were left to self-assemble overnight. The following
morning, 4 mL of phosphate-buffered saline (PBS, 0.1 M) was added on top, filling the vials. The vials
were incubated at 37 ◦C, 60 rpm, and at various timepoints. At each timepoint, 50-microliter samples
were taken and added to 0.200 mL of water to be analyzed by reverse-phase HPLC, using a Zorbax
SB-C18 Rapid Resolution HT 2.1× 50 mm column at 40 ◦C (absorbance recorded at 265 nm). The mobile
phase consisted of a mixture of H2O and MeCN containing 0.05 % TFA. The method used for the
analysis was as follows: 0–2 min, 1% MeCN; 2–12 min, 1%–95% MeCN, 12–15 min, 95% MeCN.
Each experiment was repeated six times. The average and standard deviation values were calculated
and plotted with Excel.
4.10. Molecular Modeling
The AMBER-18 suite of software [41] was used for file preparation, running molecular dynamics
(MD) simulations, and post-processing analysis in association with VMD software [42] to visualize
trajectories and in-house Python scripts for data analysis. More in detail, the D-Leu-Phe-Phe model
was parametrized by the AMBER ff14SB forcefield [43]. A well-established procedure [44], in which
partial charges are derived by applying the Restrained Electrostatic Potential (RESP method by
the RED server [45] and gaff atom types are assigned with antechamber [46,47], was employed
to prepare the 5-FU model. Two six-pair stacks of D-Leu-Phe-Phe in antiparallel and parallel
beta-sheet conformations were built in VMD based on previous structural evidences [48] (Figure S10).
Both systems were then optimized and studied according to the following strategy: a TIP3P [49]
water box was created, extending at least 1.5 nm from solute atoms, with Na+ and Cl− ions added to
neutralize the system charge. A combination of steepest descent (2500 cycles) and conjugate gradient
(2500 cycles) minimization steps running on CPU was performed in a first run restraining solute
atoms, and then releasing the solute. We then heated the simulation box to 300 K in 20 ps of NVT
ensemble simulation, and proceeded in NPT ensemble to equilibrate the system density for another
20 ps. For these first 40 ps of simulation, a 1-fs time integration step was used, and the computation
was run on the CPU. Then we switched to a 2-fs integration step and to the GPU version of the
code. The systems were equilibrated for 10 ns in NPT ensemble. Berendsen barostat [50], with a
pressure relaxation time of 1.5 ps and a target pressure of 1 bar, was used up to this stage, after which
we switched to the Monte Carlo barostat implemented in AMBER for the production runs (100 ns).
Throughout all the MD simulations, the temperature was controlled by the Langevin method [51]
(damping coefficient of 1 ps−1), and electrostatic interactions were computed by means of the particle
mesh Ewald (PME algorithm. The desired number 5-FU molecules were placed in proximity and
within the optimized stacks. Each system was equilibrated according to the procedure described above
and simulated for 1 µs of data collection.
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